Antibiotic stewardship in hospital-acquired pneumonia

Chest

Volumn 143, Issue 5, 2013, Pages 1195-1196

  Rello, Jordi ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC STEWARDSHIP; ANTIMICROBIAL THERAPY; DRUG DOSE ESCALATION; EDITORIAL; HEALTH CARE COST; HEALTH CARE QUALITY; HOSPITAL ACQUIRED PNEUMONIA; HOSPITALIZATION; HUMAN; MEDICAL DECISION MAKING; MORTALITY; MULTIDRUG RESISTANCE; NONHUMAN; OUTCOME ASSESSMENT; PNEUMONIA; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SEPTIC SHOCK; TREATMENT INDICATION; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 84877612937     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-2729     Document Type: Editorial

References (13)

1. Rello J, Sa-Borges M, Correa H, Leal SR, Baraibar J. Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices. Am J Respir Crit Care Med. 1999;160(2):608-613.
2. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44(2):159-177.
3. Rodríguez A, Díaz E, Martín-Loeches I, et al; H1N1 SEMICYUC Working Group. Impact of early oseltamivir treatment on outcome in critically ill patients with 2009 pandemic influenza A. J Antimicrob Chemother. 2011;66(5):1140-1149.
4. Sandiumenge A, Lisboa T, Gomez F, Hernandez P, Canadell L, Rello J. Effect of antibiotic diversity on ventilator-associated pneumonia caused by ESKAPE Organisms. Chest. 2011;140(3):643-651.
5. Niederman MS. De-escalation therapy in ventilator-associated pneumonia. Curr Opin Crit Care. 2006;12(5):452-457.
6. Lisboa T, Rello J. De-escalation in lower respiratory tract infections. Curr Opin Pulm Med. 2006;12(5):364-368.
7. Koulenti D, Lisboa T, Brun-Buisson C, et al EU-VAP/CAP Study Group. Spectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care units. Crit Care Med. 2009;37(8):2360-2368.
8. Martin-Loeches I, Deja M, Koulenti D, et al. Potentially-resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors. Intensive Care Med. In press.
9. Rello J, Vidaur L, Sandiumenge A, et al. De-escalation therapy in ventilator-associated pneumonia. Crit Care Med. 2004;32(11):2183-2190.
10. Vidaur L, Planas K, Sierra R, et al. Ventilator-associated pneumonia: impact of organisms on clinical resolution and medical resources utilization. Chest. 2008;133(3):625-632.
11. Chastre J, Wolff M, Fagon JY, et al; PneumA Trial Group. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003;290(19):2588-2598.
12. Vallés J, Peredo R, Burgueño MJ, et al. Efficacy of single-dose antibiotic against early-onset pneumonia in comatose patients who are ventilated. Chest. 2013;143(5):1219-1225.
13. Bal AM, Gould IM. Antibiotic stewardship: overcoming implementation barriers. Curr Opin Infect Dis. 2011;24(4):357-362.